cadenas

Innovative Therapies for Children with Cancer in Europe

  • Innovative Therapies
    for Children with Cancer in Europe
  • Contact us

Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours

ITCC Trials and the COVID19 Pandemic

A phase 1/2, open‐label, dose‐escalation study of midostaurin in children with relapsed or refractory acute leukaemia

Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer

10 year report on the European Paediatric Regulation and its impact on new drugs for children's cancers

Outcome of children and adolescents with central nervous system tumors in phase I trials

Early phase clinical trials of anticancer agents in children and adolescents — an ITCC perspective